Antitumorigenic action of nelfinavir: Effects on multiple myeloma and hematologic malignancies (Review)

  • Authors:
    • A. Allegra
    • V. Innao
    • A. G. Allegra
    • N. Pulvirenti
    • M. Pugliese
    • C. Musolino
  • View Affiliations

  • Published online on: March 26, 2020     https://doi.org/10.3892/or.2020.7562
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Protease inhibitors (PIs) inhibit HIV‑1 and HIV‑2 proteases, impeding virus replication and liberation of viral elements from infected cells. In human immunodeficiency virus (HIV) subjects receiving PI‑based treatment, an impressive decrease in the amount of HIV‑associated cancers, unconnected to viral burden or CD4 amount was observed. Research has reported that PIs have influence on cancer proliferation, spread, and survival as an effect on endoplasmic reticulum stress, proteasome, NF‑κB and Akt signalling. Nelfinavir (NFV) is a nonpeptidic PI that functions by connecting to the catalytic site of the HIV protease, thus stopping the cleavage of viral polyprotein into complete, operative proteins that are fundamental for viral survival. NFV, currently not frequently employed for antiretroviral treatment, has demonstrated noteworthy off target effects in tumor patients with or without HIV disease. NFV appears to cause cell death in tumor cells by different mechanisms, which include necrosis, apoptosis and autophagy. In this review, data from preclinical research and clinical trials are reported and the mechanisms of action of NFV and their results in the treatment of hematologic malignancies, such as acute myeloid leukemia, chronic lymphoid leukemia, and diffuse large B cell lymphoma, and especially in patients with multiple myeloma are examined. In the future, experimental studies may help identify the role of NFV in cancer treatment and may promote the application of this drug into daily clinical practice.

Related Articles

Journal Cover

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Allegra, A., Innao, V., Allegra, A.G., Pulvirenti, N., Pugliese, M., & Musolino, C. (1899). Antitumorigenic action of nelfinavir: Effects on multiple myeloma and hematologic malignancies (Review). Oncology Reports, 0, 0-0. https://doi.org/10.3892/or.2020.7562
MLA
Allegra, A., Innao, V., Allegra, A. G., Pulvirenti, N., Pugliese, M., Musolino, C."Antitumorigenic action of nelfinavir: Effects on multiple myeloma and hematologic malignancies (Review)". Oncology Reports 0.0 (1899): 0-0.
Chicago
Allegra, A., Innao, V., Allegra, A. G., Pulvirenti, N., Pugliese, M., Musolino, C."Antitumorigenic action of nelfinavir: Effects on multiple myeloma and hematologic malignancies (Review)". Oncology Reports 0, no. 0 (1899): 0-0. https://doi.org/10.3892/or.2020.7562